Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Iambic Therapeutics Presents Updated Clinical Results From Its IAM1363 Inhibitor At ESMO Congress 2026
Iambic Therapeutics (IAM) Filed An IND For IAM217
Iambic Announces Pricing of Initial Public Offering
Iambic Therapeutics Starts IPO Effort On Broad Collaboration Relationships
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
